These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

715 related items for PubMed ID: 16498805

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon beta: implications for clinical trials.
    Río J, Nos C, Tintoré M, Borrás C, Galán I, Comabella M, Montalban X.
    Ann Neurol; 2002 Oct; 52(4):400-6. PubMed ID: 12325067
    [Abstract] [Full Text] [Related]

  • 3. Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience.
    Pozzilli C, Prosperini L, Sbardella E, De Giglio L, Onesti E, Tomassini V.
    Neurol Sci; 2005 Dec; 26 Suppl 4():S174-8. PubMed ID: 16388353
    [Abstract] [Full Text] [Related]

  • 4. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients.
    Río J, Nos C, Tintoré M, Téllez N, Galán I, Pelayo R, Comabella M, Montalban X.
    Ann Neurol; 2006 Feb; 59(2):344-52. PubMed ID: 16437558
    [Abstract] [Full Text] [Related]

  • 5. Effects of relapsing-remitting multiple sclerosis treatment with interferon beta-1b results of a three-year follow-up study.
    Jesić A, Stefanović D, Delibasić N, Semnic M, Sakallasz L, Dobrenov D, Zivanović Z, Rabi-Zikić T, Zikić M.
    Acta Clin Croat; 2009 Jun; 48(2):183-6. PubMed ID: 19928420
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
    Kappos L, Traboulsee A, Constantinescu C, Erälinna JP, Forrestal F, Jongen P, Pollard J, Sandberg-Wollheim M, Sindic C, Stubinski B, Uitdehaag B, Li D.
    Neurology; 2006 Sep 26; 67(6):944-53. PubMed ID: 17000959
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis.
    Etemadifar M, Janghorbani M, Shaygannejad V.
    Acta Neurol Scand; 2006 May 26; 113(5):283-7. PubMed ID: 16629762
    [Abstract] [Full Text] [Related]

  • 11. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.
    Río J, Rovira A, Tintoré M, Huerga E, Nos C, Tellez N, Tur C, Comabella M, Montalban X.
    Mult Scler; 2008 May 26; 14(4):479-84. PubMed ID: 18562504
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Long-term application of the multiple sclerosis functional composite test in Debrecen, Hungary].
    Mezei Z, Bereczki D, Csiba L, Csépány T.
    Ideggyogy Sz; 2006 Nov 20; 59(11-12):442-7. PubMed ID: 17203882
    [Abstract] [Full Text] [Related]

  • 14. A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis.
    Koch-Henriksen N, Sørensen PS, Christensen T, Frederiksen J, Ravnborg M, Jensen K, Heltberg A, Kristensen O, Stenager E, Petersen T, Hansen T, Danish Multiple Sclerosis Group.
    Neurology; 2006 Apr 11; 66(7):1056-60. PubMed ID: 16510769
    [Abstract] [Full Text] [Related]

  • 15. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.
    Koch-Henriksen N, Sorensen PS, Bendtzen K, Flachs EM.
    Mult Scler; 2009 May 11; 15(5):601-5. PubMed ID: 19299439
    [Abstract] [Full Text] [Related]

  • 16. Prospective clinical and electrophysiological follow-up on a multiple sclerosis population treated with interferon beta-1 a: a pilot study.
    Feuillet L, Pelletier J, Suchet L, Rico A, Ali Cherif A, Pouget J, Attarian S.
    Mult Scler; 2007 Apr 11; 13(3):348-56. PubMed ID: 17439904
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study.
    Lugaresi A, Durastanti V, Gasperini C, Lai M, Pozzilli C, Orefice G, Sotgiu S, Pucci E, Ardito B, Millefiorini E, CoSa Study Group.
    Clin Neuropharmacol; 2008 Apr 11; 31(3):167-72. PubMed ID: 18520983
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.